Reactivation of chronic hepatitis B during treatment with tenofovir disoproxil fumarate: drug interactions or low adherence?

Caroleo, Benedetto; Staltari, Orietta; Gallelli, Luca; Perticone, Francesco

doi:10.1136/bcr-2015-209586

Cited by 7 publications

(4 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In agreement with our previous studies [19][20][21][22], using the Naranjo probability scale, we documented a possible association between severe panniculitis and panitumumab in two women with mCRC (Naranjo score 6) that required a treatment with corticosteroids and empirical antimicrobial drugs.…”

Section: Discussionsupporting

confidence: 92%

Panitumumab Induced Forearm Panniculitis in Two Women With Metastatic Colon Cancer

Ciliberto

Ierardi

Caroleo

et al. 2019

CDS

Self Cite

View full text Add to dashboard Cite

Background: Panitumumab is an EGFR inhibitor used for the treatment of metastatic colorectal cancer (mCRC), even if its use is related to skin toxicity. Case Presentation: We report the development of forearm panniculitis in two women during the treatment with Panitumumab (6 mg/Kg intravenous every 2 weeks) + FOLFOX-6 (leucovorin, 5- fluorouracil, and oxaliplatin at higher dosage) for the treatment of mCRC. Results: In both patients, clinical, laboratory and radiological evaluation documented the presence of a local panniculitis, probably related to panitumumab (Naranjo score: 6). Panatimumab discontinuation and antimicrobial + corticosteroid treatment induced a remission of skin manifestations. Conclusion: We reported for the first time the development of panniculitis during Panitumumab treatment, and we documented that the treatment with beta-lactams to either fluoroquinolones or oxazolidinone in the presence of corticosteroid improves clinical symptoms in young patients with mCRC, without the development of adverse drug reactions or drug-drug interactions.

show abstract

Section: Discussionsupporting

confidence: 92%

Panitumumab Induced Forearm Panniculitis in Two Women With Metastatic Colon Cancer

Ciliberto

Ierardi

Caroleo

et al. 2019

CDS

Self Cite

View full text Add to dashboard Cite

show abstract

“…The development of adverse drug reactions and drug interactions was evaluated during the whole period of the study (T1-T5) in agreement with our previous papers. [11][12][13][14][15][16] End Points…”

Section: Assessment Of Safetymentioning

confidence: 99%

Efficacy and Safety of Elbasvir‐Grazoprevir Fixed Dose in the Management of Polytreated HCV Patients: Evidence From Real‐Life Clinical Practice

Caroleo

Colangelo

Perticone

et al. 2018

The Journal of Clinical Pharma

Self Cite

View full text Add to dashboard Cite

Chronic hepatitis C virus (HCV) infection represents a global public health challenge, and new drugs have been authorized for its treatment. In this study, we evaluated both the clinical efficacy and safety of elbasvir-grazoprevir fixed-dose combination in HCV patients. We performed a prospective single-blind study on patients admitted to the Regional Center for HCV Treatment of the University of Catanzaro from March 1, 2017, to December 31, 2017, in patients >30 years old with a history of chronic HCV infection. During the study period, we enrolled 29 HCV patients (18 women and 11 men; age, 62.5 ± 14 years, range 36-82; HCV-RNA: 2 384 859 ± 2 487 747 IU/mL, range, 60 400 - 8 930 000 IU/mL genotype 1b). In 28 of 29 patients (96.5%) we documented a rapid and complete remission of HCV infection 4 weeks after the beginning of the treatment, while in 1 patient it was reached in 8 weeks. During the study, we did not record any serious adverse drug reaction or drug interaction and no patients discontinued the treatment. However, 4 patients (13.8%) developed an asymptomatic plasma transaminase increase that appeared at 8 weeks after the beginning of the treatment and disappeared 4 weeks later in 3 patients and 8 weeks later in 1 patient. In conclusion, we documented that in real life the development of plasma transaminase increase in 4 elderly women >70 years old, suggesting that more attention must be focused on this age population.

show abstract

“…[ 14 ] In our experience, we observed a case of figurative urticaria characterized by annular, ovular, and polycyclic shaped lesions with well-defined itchy margins that followed the administration of etanercept. Considering the potential role of drug-drug interactions in inducing adverse events in HBV patients,[ 15 16 ] we assessed the interactions using the software Micromedex 2.0 (Truven Health Analytics, Inc. Greenwood Village, Colarodo). No drug-drug interactions were detected between lamivudine and etanercept.…”

Section: Discussionmentioning

confidence: 99%

A case of figurate urticaria by etanercept

Sessa¹,

Sullo²,

Mascolo³

et al. 2016

Journal of Pharmacology and Pharmacotherapeutics

View full text Add to dashboard Cite

Etanercept is a competitive inhibitor of tumor necrosis factor-alpha (TNF-α) a polypeptide hormone, involved in the development of the immune system, in host defense and immune surveillance. Even if the etanercept mechanism of action is not completely understood, it is supposed that it negatively modulates biological responses mediated by molecules (cytokines, adhesion molecules, or proteinases) induced or regulated by TNF. For this reason, it is widely used in the treatment of immunologicals diseases, such as rheumatoid and psoriatic arthritis, polyarticular juvenile idiopathic active, ankylosing spondylitis, and plaque psoriasis. Etanercept has a good tolerability profile. Adverse events related to skin are rare, arising usually in about 5% of patients treated with anti-TNF α. In this scenario, we describe a case of figurate urticaria arose after the re-administration of etanercept in a patient affected by psoriasis and hepatitis B. A 65-year-old man, affected by psoriasis, was hospitalized in September 2014 to the Regional Center for the treatment of psoriasis and Biological Drugs of Second University of Naples for progressive extension of psoriatic skin lesions. The laboratory analysis detected positivity for hepatitis B virus (HBV) antigens. For this reason, it was administered to him lamivudine 100 mg/die about 30 days before to start etanercept treatment. The etanercept therapy has resulted in a progressive improving of skin manifestations, and the patient decided individually to stop the therapy. Afterwards, for worsening of the psoriatic lesions, he was again hospitalized and treated with the same therapeutic schedule (lamivudine followed by etanercept). Ten days after the start of therapy, the patient showed the onset of urticarial rash. Due to this, the treatment with lamivudine and etanercept was suspended and the patient's clinical conditions improved. It is probably that immunological disorders due to etanercept therapy and HBV infection could explain the onset of figurate urticaria in our patient. In this contest, the post-marketing surveillance confirms its important role in the monitoring of drugs tolerability and effectiveness.

show abstract

Reactivation of chronic hepatitis B during treatment with tenofovir disoproxil fumarate: drug interactions or low adherence?

Cited by 7 publications

References 33 publications

Panitumumab Induced Forearm Panniculitis in Two Women With Metastatic Colon Cancer

Panitumumab Induced Forearm Panniculitis in Two Women With Metastatic Colon Cancer

Efficacy and Safety of Elbasvir‐Grazoprevir Fixed Dose in the Management of Polytreated HCV Patients: Evidence From Real‐Life Clinical Practice

A case of figurate urticaria by etanercept

Contact Info

Product

Resources

About